Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Phase I/II trial of tremelimumab in patients with metastatic melanoma.

Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A.

J Clin Oncol. 2009 Mar 1;27(7):1075-81. doi: 10.1200/JCO.2008.19.2435. Epub 2009 Jan 12.

PMID:
19139427
2.

Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.

Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA, Gomez-Navarro J, Cochran AJ.

Clin Cancer Res. 2009 Jan 1;15(1):390-9. doi: 10.1158/1078-0432.CCR-08-0783.

3.

Phase I/II study of ipilimumab for patients with metastatic melanoma.

Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E.

J Clin Oncol. 2008 Dec 20;26(36):5950-6. doi: 10.1200/JCO.2008.16.1927. Epub 2008 Nov 17.

PMID:
19018089
4.

CTLA-4 control over Foxp3+ regulatory T cell function.

Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, Nomura T, Sakaguchi S.

Science. 2008 Oct 10;322(5899):271-5. doi: 10.1126/science.1160062.

5.

Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?

Ménard C, Ghiringhelli F, Roux S, Chaput N, Mateus C, Grohmann U, Caillat-Zucman S, Zitvogel L, Robert C.

Clin Cancer Res. 2008 Aug 15;14(16):5242-9. doi: 10.1158/1078-0432.CCR-07-4797.

6.

Induction and effector functions of T(H)17 cells.

Bettelli E, Korn T, Oukka M, Kuchroo VK.

Nature. 2008 Jun 19;453(7198):1051-7. doi: 10.1038/nature07036. Review.

PMID:
18563156
7.

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion.

Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L.

Blood. 2008 Aug 15;112(4):1175-83. doi: 10.1182/blood-2007-11-125435. Epub 2008 Jun 3.

8.

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.

Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J, Ribas A.

J Transl Med. 2008 May 1;6:22. doi: 10.1186/1479-5876-6-22.

9.

Memory Th-17 cells specific for C. albicans are persistent in human peripheral blood.

Zhou M, Yang B, Ma R, Wu C.

Immunol Lett. 2008 Jun 15;118(1):72-81. doi: 10.1016/j.imlet.2008.03.004. Epub 2008 Apr 9.

PMID:
18440075
10.

Tumor-specific Th17-polarized cells eradicate large established melanoma.

Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC, Restifo NP.

Blood. 2008 Jul 15;112(2):362-73. doi: 10.1182/blood-2007-11-120998. Epub 2008 Mar 19.

11.

The inflammatory Th 17 subset in immunity against self and non-self antigens.

Jin D, Zhang L, Zheng J, Zhao Y.

Autoimmunity. 2008 Mar;41(2):154-62. doi: 10.1080/08916930701776605. Review.

PMID:
18324485
12.

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6681-8. Epub 2007 Nov 2.

13.

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.

Ribas A, Hanson DC, Noe DA, Millham R, Guyot DJ, Bernstein SH, Canniff PC, Sharma A, Gomez-Navarro J.

Oncologist. 2007 Jul;12(7):873-83. Review.

14.

Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment.

Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, Chang A, Zou W.

J Immunol. 2007 Jun 1;178(11):6730-3.

15.

T(H)-17 cells in the circle of immunity and autoimmunity.

Bettelli E, Oukka M, Kuchroo VK.

Nat Immunol. 2007 Apr;8(4):345-50. Review.

PMID:
17375096
16.

Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17.

Nakae S, Iwakura Y, Suto H, Galli SJ.

J Leukoc Biol. 2007 May;81(5):1258-68. Epub 2007 Feb 16.

PMID:
17307864
17.

Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis.

Röhn TA, Jennings GT, Hernandez M, Grest P, Beck M, Zou Y, Kopf M, Bachmann MF.

Eur J Immunol. 2006 Nov;36(11):2857-67.

18.

Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis.

Sonderegger I, Röhn TA, Kurrer MO, Iezzi G, Zou Y, Kastelein RA, Bachmann MF, Kopf M.

Eur J Immunol. 2006 Nov;36(11):2849-56.

19.

IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis.

Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura Y.

J Immunol. 2006 Jul 1;177(1):566-73.

20.

Critical role of IL-17 receptor signaling in acute TNBS-induced colitis.

Zhang Z, Zheng M, Bindas J, Schwarzenberger P, Kolls JK.

Inflamm Bowel Dis. 2006 May;12(5):382-8.

PMID:
16670527

Supplemental Content

Support Center